According to the new market research report Breast Cancer Liquid Biopsy Market is expected to reach USD 411.1 million by 2022, at a CAGR of 23.1%. The key features driving the growth of this market include increasing prevalence of breast cancer, increasing preference for non-invasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150106081
North America dominated the market in 2017
North America accounted for the largest share of the breast cancer liquid biopsy market in 2017, followed by Europe. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of breast cancer in the US and Canada, technological advancements in breast cancer liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region.
The key players in the global breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
QIAGEN was the leading player in the breast cancer liquid biopsy market in 2017. The company is a global provider of sample-to-insight solutions that aids in the transformation of biological samples into molecular insights. The company operates through its two business segments, namely, instruments and consumables & related products.
By end user, the reference laboratories segment accounted for the largest market share in 2017
Based on end user, the breast cancer liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, and other end users (research institutes, public health laboratories, pathology laboratories, and small molecular laboratories). Reference laboratories form the largest and fastest-growing end-user segment of the liquid biopsy market. The large share of this segment is attributed to the increasing volume of liquid biopsy test samples outsourced to reference laboratories owing to their well-equipped set up for genetic testing.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=150106081
By circulating biomarkers, cell-free DNA (cfDNA) is expected to account for the largest market share in 2017
Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vehicles (EVs), and other circulating biomarkers. In 2017, the cfDNA segment is expected to account for the largest share of the breast cancer liquid biopsy market. The ability of cfDNA for easy and early assessment of patient prognosis and occurrence in other body fluids along with blood is driving the growth of the cfDNA segment in the breast cancer liquid biopsy market.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
[email protected]
Breast Cancer Liquid Biopsy Market 2017 – 2022 | Industry Report
Breast cancer is considered to be the second most common malignancy in the world, and therefore, liquid biopsy is a very important tool for breast cancer diagnosis and determination.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=51546 According to the World Health Organization (WHO), breast cancer is the most frequently occurring cancer among women.
It affects 2.1 million women each year and results in the highest number of cancer-related deaths among women.
While rates of breast cancer are higher among women in more developed regions, rates are elevating in nearly every region globally.Key drivers of the breast cancer liquid biopsy market include rise in the prevalence of breast cancer, increase in propensity for non-invasive procedures, rise in awareness about cancer, increase in health care expenditure, and initiatives and measures taken by government and global health organizations.
Moreover, intensive research and development in the field of cancer, technological advancements, and an inclination toward personalized medicine are expected to enhance the growth of the market.
However, insufficiency of trained professionals, high cost of the tests, and fewer reimbursement policies are expected to hinder the global breast cancer liquid biopsy market.Request COVID Analysis on Liquid Biopsy Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=51546 Based on circulating biomarkers, the global breast cancer liquid biopsy market can be classified into cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other circulating biomarkers.
The cell-free DNA (cfDNA) segment is expected to hold a prominent share of the breast cancer liquid biopsy market.
Know more about breast cancer causes, symptoms, and treatment Breast cancer can be diagnosed through multiple tests, including a mammogram, ultrasound, MRI, and biopsy.
Breast Cancer Treatment in Gurugram, Gurgaon, Haryana
Breast cancer is considered to be the second most common malignancy in the world, and therefore, liquid biopsy is a very important tool for breast cancer diagnosis and determination.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=51546 According to the World Health Organization (WHO), breast cancer is the most frequently occurring cancer among women.
It affects 2.1 million women each year and results in the highest number of cancer-related deaths among women.
While rates of breast cancer are higher among women in more developed regions, rates are elevating in nearly every region globally.Key drivers of the breast cancer liquid biopsy market include rise in the prevalence of breast cancer, increase in propensity for non-invasive procedures, rise in awareness about cancer, increase in health care expenditure, and initiatives and measures taken by government and global health organizations.
Moreover, intensive research and development in the field of cancer, technological advancements, and an inclination toward personalized medicine are expected to enhance the growth of the market.
However, insufficiency of trained professionals, high cost of the tests, and fewer reimbursement policies are expected to hinder the global breast cancer liquid biopsy market.Request COVID Analysis on Liquid Biopsy Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=51546 Based on circulating biomarkers, the global breast cancer liquid biopsy market can be classified into cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other circulating biomarkers.
The cell-free DNA (cfDNA) segment is expected to hold a prominent share of the breast cancer liquid biopsy market.
Know more about breast cancer causes, symptoms, and treatment Breast cancer can be diagnosed through multiple tests, including a mammogram, ultrasound, MRI, and biopsy.
Breast Cancer Treatment in Gurugram, Gurgaon, Haryana